Cash Flow Statement

Amortizatization of Intangibles Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Free Cash Flow Gains from Investment Securities Net Cash Flow Net Income Non-cash Items Other Working Capital Changes Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Pyxis Oncology (PYXS) Change in Receivables (2024)

Pyxis Oncology (PYXS) has disclosed Change in Receivables for 1 consecutive years, with $8.0 million as the latest value for Q1 2024.